KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cerence (CRNC) Cash & Equivalents (2019 - 2025)

Cerence's Cash & Equivalents history spans 7 years, with the latest figure at $92.1 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 11.5% year-over-year to $92.1 million; the TTM value through Dec 2025 reached $92.1 million, down 11.5%, while the annual FY2025 figure was $84.0 million, 30.84% down from the prior year.
  • Cash & Equivalents reached $92.1 million in Q4 2025 per CRNC's latest filing, up from $84.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $128.4 million in Q3 2021 to a low of $17.7 million in Q2 2022.
  • Average Cash & Equivalents over 5 years is $99.5 million, with a median of $100.2 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: crashed 85.34% in 2022, then soared 385.97% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $117.2 million in 2021, then dropped by 22.67% to $90.7 million in 2022, then increased by 8.91% to $98.7 million in 2023, then grew by 5.44% to $104.1 million in 2024, then dropped by 11.5% to $92.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRNC's Cash & Equivalents are $92.1 million (Q4 2025), $84.0 million (Q3 2025), and $73.7 million (Q2 2025).